Levothyroxine Therapy in Thyrodectomized Patients
- PMID: 33584551
- PMCID: PMC7878675
- DOI: 10.3389/fendo.2020.626268
Levothyroxine Therapy in Thyrodectomized Patients
Abstract
Administration of the optimal dose of levothyroxine (LT4) is crucial to restore euthyroidism after total thyroidectomy. An insufficient or excessive dosage may result in hypothyroidism or thyrotoxicosis, either one associated with a number of symptoms/complications. Most literature regarding the LT4 dosage deals with the treatment of primary hypothyroidism, whereas a limited number of studies handle the issue of thyroxin replacement after total thyroidectomy. A literature review was performed focusing on all papers dealing with this topic within the last 15 years. Papers that reported a scheme to calculate the proper LT4 dose were collected and compared to set up a review exploring limits and drawbacks of LT4 replacement therapy in the wide population of patients who had undergone thyroidectomy. Most of the methods for monitoring and adjusting thyroid hormone replacement after thyroidectomy for benign disease use LT4 at an empirical dose of approximately 1.6 μg/kg, with subsequent changes according to thyroid function test results and assessments of the patient's symptoms. Approximately 75% of patients require a dose adjustment, suggesting that factors other than body weight play a role in the determination of the proper LT4 dose. Hence, several schemes are reported in the literature for the proper initial dose of LT4. An inadequate level of thyroid hormone levels in these patients can be due to several factors. The most common ones that lead to the necessity of LT4 dose adjustments include lack of compliance, changes in LT4 formulation, dosage errors, increased serum levels of T4-binding globulin, body mass changes, and dietary habits. Moreover, concomitant ingestion of calcium supplements, ferrous sulfate, proton-pump inhibitors, bile acid sequestrants, and sucralfate might influence LT4 absorption and/or metabolism. Furthermore, some gastrointestinal conditions and their treatments can contribute to suboptimal LT4 performance by altering gastric acidity and thereby reducing its bioavailability, particularly in the solid form. Beyond the classic tablet form, new formulations of LT4, such as a soft gel capsule and an oral solution, recently became available. The liquid formulation is supposed to overcome the food and beverages interference with absorption of LT4 tablets.
Keywords: levothyroxine; levothyroxine dose; liquid levothyroxine; thyroid; thyroidectomy.
Copyright © 2021 Miccoli, Materazzi and Rossi.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Patient-Tailored Levothyroxine Dosage with Pharmacokinetic/Pharmacodynamic Modeling: A Novel Approach After Total Thyroidectomy.Thyroid. 2021 Sep;31(9):1297-1304. doi: 10.1089/thy.2021.0125. Epub 2021 Jun 22. Thyroid. 2021. PMID: 33980057 Free PMC article. Clinical Trial.
-
Efficacy of Levothyroxine Sodium Soft Gelatin Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors: An Open-Label Study.Thyroid. 2023 Dec;33(12):1414-1422. doi: 10.1089/thy.2023.0382. Epub 2023 Nov 16. Thyroid. 2023. PMID: 37885233 Free PMC article.
-
LEVOTHYROXINE REPLACEMENT IN OBESE HYPOTHYROID FEMALES AFTER TOTAL THYROIDECTOMY.Endocr Pract. 2016 Jan;22(1):22-9. doi: 10.4158/EP15836.OR. Epub 2015 Oct 5. Endocr Pract. 2016. PMID: 26437220
-
New Formulations of Levothyroxine in the Treatment of Hypothyroidism: Trick or Treat?Thyroid. 2021 Feb;31(2):193-201. doi: 10.1089/thy.2020.0515. Epub 2020 Nov 2. Thyroid. 2021. PMID: 33003978 Review.
-
Levothyroxine Formulations: Pharmacological and Clinical Implications of Generic Substitution.Adv Ther. 2019 Sep;36(Suppl 2):59-71. doi: 10.1007/s12325-019-01079-1. Epub 2019 Sep 4. Adv Ther. 2019. PMID: 31485974 Free PMC article. Review.
Cited by
-
Efficacy of Combined Photobiomodulation Therapy with Supplements versus Supplements alone in Restoring Thyroid Gland Homeostasis in Hashimoto Thyroiditis: A Clinical Feasibility Parallel Trial with 6-Months Follow-Up.J Pers Med. 2023 Aug 19;13(8):1274. doi: 10.3390/jpm13081274. J Pers Med. 2023. PMID: 37623524 Free PMC article.
-
A predictive model for L-T4 dose in postoperative DTC after RAI therapy and its clinical validation in two institutions.Front Endocrinol (Lausanne). 2024 Aug 20;15:1425101. doi: 10.3389/fendo.2024.1425101. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39229373 Free PMC article.
-
A Clinical Audit of Thyroid Hormonal Replacement After Total Thyroidectomy.Cureus. 2023 Dec 12;15(12):e50374. doi: 10.7759/cureus.50374. eCollection 2023 Dec. Cureus. 2023. PMID: 38116025 Free PMC article.
-
Levothyroxine therapy in thyroidectomized patients: ongoing challenges and controversies.Front Endocrinol (Lausanne). 2025 May 26;16:1582734. doi: 10.3389/fendo.2025.1582734. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40491597 Free PMC article. Review.
-
ETA guidelines for the use of levothyroxine sodium preparations in monotherapy to optimize the treatment of hypothyroidism.Eur Thyroid J. 2025 Jul 31;14(4):e250123. doi: 10.1530/ETJ-25-0123. Print 2025 Aug 1. Eur Thyroid J. 2025. PMID: 40622204 Free PMC article.
References
-
- Benvenga S, Pantano R, Saraceno G, Lipari L, Alibrando A, Inferrera S, et al. A minimum of two years of undertreated primary hypothyroidism, as a T result of drug-induced malabsorption of L-thyroxine, may have metabolic and cardiovascular consequences. J Clin Transl Endocrinol (2019) 16:100189. 10.1016/j.jcte.2019.100189 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources